Project Grant R43TR005143
Award Date
7/15/24
Completion Date
6/30/26
Dollars Obligated
$176K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Morrisville, NC, USA
Similar Awards
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA 93.350 Federal Grant Program, awarded a $1,334,242 Project Grant to Cellchorus Inc., a for-profit company based in Houston, Texas. The grant, with a period of performance from May 1, 2024 to April 30, 2027, will fund the development and optimization of Cellchorus' "TIMING" platform, an AI-powered, high-resolution single-cell analysis technology. The key objectives of this project are to: (i) develop and...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 provides $317,029 to Chemia Biosciences, Inc., a small disadvantaged business, to develop advanced computational technologies for discovering novel antimicrobial natural products. The primary goals are to create software that can predict the molecular structures of natural products encoded in microbial genomes, with a focus on identifying new antimicrobial polysaccharides and...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training Program provides $733,376 to the Georgia Tech Research Corporation to develop and apply new predictive medicine technology. The key products and services to be delivered include: Integration of biomedical literature and development of a comprehensive knowledge graph software called SemBioSys to enable cross-disciplinary discovery. High-throughput...
This $5,611,892 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS), under CFDA Program 93.859 Biomedical Research and Research Training, is intended to fund the development, optimization, and commercialization of UltraMarathonRT, a new enzyme for unbiased transcriptomic and epitranscriptomic characterization of RNAs. The award to RNAConnect, Inc. in Branford, CT will enable the creation of a family of commercial products that boost the sensitivity of RT-PCR and...
The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 program, awarded a $297,608 Project Grant to Chimerna Therapeutics, Inc. to develop a yeast-based manufacturing platform for producing high-quality circular RNAs (circRNAs). Chimerna Therapeutics is a biotechnology company focused on advancing novel RNA-based therapeutics, particularly circRNAs. The project aims to engineer yeast strains capable of expressing circRNAs at high yields, addressing key...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $335,944 to Vanderbilt University from Sep 1, 2024 to Aug 31, 2027 to further develop, refine, and validate their emerging free-solution assay (FSA) technology and compensated interferometric reader (CIR). The FSA-CIR platform represents a novel, label-free, solution-phase, ultra-sensitive, enzyme-free technology that is compatible with a wide range of biological matrices. It enables...
This Federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under its Biomedical Research and Research Training program (CFDA 93.859), aims to develop a neural network-accelerated DNA and RNA sequence processing node called CLEDGESEQ. The $350,000 award to Quantitative Biosciences, Inc., a for-profit company in San Diego, California, supports the following key objectives: Develop neural network-based routines for accelerating next-generation...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) is focused on improving the clinical sensitivity of circulating tumor DNA (ctDNA) liquid biopsies for cancer detection and management. The $670,147 award to Vanderbilt University Medical Center (VUMC) aims to enhance the ability of ctDNA tests to distinguish between patients with and without cancer by better understanding the molecular mediators of cell-free...